• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Multiple myeloma management with lenalidomide, bortezomib and dexamethasone associated with prolonged progression-free survival

byAndrew Cheung, MD MBAandNeil D'Souza
April 7, 2017
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The use of lenalidomide, bortezomib and dexamethasone (RVD) with transplantation was associated with a significantly longer progression-free survival compared to RVD therapy alone.

2. There was no difference in overall survival between the two therapeutic approaches.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: The standard of therapy for newly diagnosed multiple myeloma patients less than 65 years old has been high-dose chemotherapy and autologous stem-cell transplant. The associated toxicity and requirement for hospitalization during treatment has given rise to using of immunomodulatory drugs and proteasome inhibitors. More importantly, the combination of these agents has improved rates of complete response and outcomes, for both transplant and non-transplant eligible patients. Though these benefits exist, there remains questions regarding the timing and role of transplantation. As such, this phase 3 trial compared induction with 3 cycles of RVD, consolidation with a further 5 cycles of RVD, then 2 additional cycles of RVD, versus 3 cycles of RVD, consolidation with high-dose melphalan and stem-cell transplantation, then 2 additional cycles of RVD. Both arms received lenalidomide maintenance therapy for 1 year. The transplantation arm had longer median progression free survival compared to RVD alone. However, there was no difference in overall survival, and the transplantation arm had higher rates of neutropenia, gastrointestinal disorders and infections. The major strength of this study is its methods randomized controlled trial) and large study numbers, significant enough to power the study and enable valid conclusions to be drawn.

Click to read the study in NEJM

Relevant Reading: Autologous transplantation and maintenance therapy in multiple myeloma

RELATED REPORTS

Talquetamab and teclistamab combination improved response in relapsed multiple myeloma

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients

In-Depth [randomized controlled trial]: This study examined the impact of transplantation in treating multiple myeloma patients under the age of 65. Randomization was to either induction with 3 cycles of RVD, consolidation with a further 5 cycles of RVD, then 2 additional cycles of RVD, versus 3 cycles of RVD, consolidation with high-dose melphalan and stem-cell transplantation, then 2 additional cycles of RVD. The primary endpoint was progression-free survival.

Of the 764 patients screened for study eligibility, 700 patients were ultimately enrolled in the study, 350 were randomized to the transplant arm and 350 to the RVD alone arm. The rate of complete response was 48% in the RVD-along group versus 59% in the transplantation group (p = 0.03). The median duration of follow-up after randomization was 44 months in the RVD-alone group, and 43 months in the transplantation group. Median progression-free survival was 36 months in the RVD-alone group, versus 50 months in the transplantation group (adjusted HR for disease progression or death, 0.65; 95%CI 0.53-0.80; p < 0.001. Overall survival between the two groups at 4 years did not significantly differ (82% RVD-alone, versus 81% transplantation; HR 1.16, 95%CI 0.80 -1.68; p = 0.87). In terms of toxicity, grade 3 or 4 adverse events were significantly more common in the transplantation group compared to the RVD-alone group with respect to hemapoetic and lymphatic-system disorders (95%vs 64%, p < 0.001), gastrointestinal disorders (28% vs 7%, p < 0.001), and infections (29% vs 9%, p < 0.001).

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: multiple myeloma
Previous Post

2 Minute Medicine Rewind April 3, 2017

Next Post

No link between antenatal betamethasone and abnormal childhood bone development

RelatedReports

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor
Chronic Disease

Talquetamab and teclistamab combination improved response in relapsed multiple myeloma

March 6, 2025
#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma
StudyGraphics

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

December 26, 2024
Phase III trial shows survival benefit for early multiple myeloma
Pharma

Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients

October 22, 2024
#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone
StudyGraphics

#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone

August 16, 2024
Next Post
AAP addresses neonatal pain prevention

No link between antenatal betamethasone and abnormal childhood bone development

Long-term outcomes for off-pump and on-pump CABG are similar

Weight fluctuations associated with mortality in patients with coronary artery disease

Long term phototherapy can enhance treatment response in vitiligo

Long term phototherapy can enhance treatment response in vitiligo

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.